U.S. markets close in 6 hours 12 minutes

Immutep Limited (IMMP)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.2896-0.0104 (-0.45%)
As of 09:41AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close2.3000
Bid2.2400 x 1000
Ask2.5000 x 800
Day's Range2.2700 - 2.3000
52 Week Range1.5000 - 3.9000
Avg. Volume136,988
Market Cap272.194M
Beta (5Y Monthly)1.81
PE Ratio (TTM)N/A
EPS (TTM)-0.3500
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.66
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for IMMP

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Immutep Limited
    Daily – Vickers Top Buyers & Sellers for 02/22/2024The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    11 days agoArgus Research
View more
  • Simply Wall St.

    Individual investors account for 60% of Immutep Limited's (ASX:IMM) ownership, while institutions account for 29%

    Key Insights Immutep's significant individual investors ownership suggests that the key decisions are influenced by...

  • Insider Monkey

    10 Best Australian Stocks To Buy

    In this piece, we will take a look at the ten best Australian stocks to buy. If you want to skip our coverage of some of the biggest stocks in Australia and how you might trade them, then you can skip ahead to 5 Best Australian Stocks To Buy. When we talk about the fundamentals […]

  • GlobeNewswire

    Immutep Quarterly Activities Report Q2 FY24

    Media Release Excellent clinical data reported from TACTI-002 Phase II trial, including median Overall Survival of 35.5 months in first line non-small cell lung cancer (1L NSCLC) patients expressing PD-L1 (TPS ≥1%)Promising efficacy and tolerability data reported from INSIGHT-003 Phase I trial, including a strong Overall Response Rate of 71.4% in 1L NSCLC patientsLate-stage & registrational trial progress: 1L NSCLC: constructive regulatory feedback received for registrational TACTI-004 Phase III